New research presented by Amplia Therapeutics (ASX:ATX) is drawing attention to a potential strategy that could improve the effectiveness of an emerging class of cancer treatments targeting KRAS mutations, one of the most widely studied drivers of solid tumours worldwide. …
New cancer research highlights potential of narmafotinib to koost KRAS Inhibitor therapies
March 9, 2026 Australian Biotech
Latest Video
New Stories
-
The 'Dispatched' Week in Review' Podcast - 27 March
March 27, 2026 - - Podcast -
The unseen price of survival for women facing early breast cancer in Australia
March 27, 2026 - - Latest News -
This is the not so quiet demand and doctrine of rationed health care
March 27, 2026 - - Latest News -
If these can be presented as positives, then we really have become accustomed to terrible
March 26, 2026 - - Latest News -
Liberty expands into Asia Pacific life sciences insurance with new tailored offering
March 25, 2026 - - Australian Biotech -
Budget delivers progress, but hundreds of thousands still waiting for access
March 25, 2026 - - Latest News -
To what extent does the system even see itself as bound by external review?
March 25, 2026 - - Latest News